Hyderabad: Gland Pharma Limited and Neuland Laboratories Limited have entered into a long-term strategic Contract Development and Manufacturing Organisation (CDMO) partnership to strengthen sterile active pharmaceutical ingredient (API) manufacturing capabilities for global pharmaceutical customers. Under the collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite for APIs used in microparticle depot products at its JNPC manufacturing facility in Visakhapatnam. The new facility will support Neuland Laboratories' growing demand for sterile APIs while expanding Gland Pharma's sterile manufacturing infrastructure. Commenting on the partnership, Srinivas Sadu, Executive Chairman of Gland Pharma, said, "We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. "Through this partnership with Gland Pharma, we are combining Neuland's expertise in complex APIs with Gland's proven sterile manufacturing capabilities to create a differentiated platform for global customers.